Lantern Pharma Inc. (LTRN)
Data as of , from SEC Form 4 filings.
See up to 3 months of LTRN. The 7-day demo opens the 1M and 3M ranges and puts LTRN on your watchlist.
Start 7-day demoLatest LTRN insider trades
About Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
- DALLAS, TX
- 16
- 2020
- Nasdaq
LTRN Form 4 activity by transaction type, last 90 days
No Form 4 activity for LTRN in the last 90 days.
LTRN insider transactions (Form 4)
3916 Form 4 filings on record, the earliest from Aug 19, 2025, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lee Troy Schalop - Director | Open-market purchase | Common stock, $0.001 par value | 48,544 footnote F1 | $2.06 | $100K | |
| Lee Troy Schalop - Director | Open-market purchase | Common stock purchase warrant (Right to Buy) | 48,544 footnote F1 | $0.00 | - | |
| ||||||
| D. Jeffrey Keyser - Director | Open-market purchase | Common stock, $0.001 par value | 48,544 footnote F1 | $2.06 | $100K | |
| D. Jeffrey Keyser - Director | Open-market purchase | Common stock purchase warrant (Right to Buy) | 48,544 footnote F1 | $0.00 | - | |
| ||||||
| D. Jeffrey Keyser - Director | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| D. Jeffrey Keyser - Director | Grant or award | Stock Option (Right to Buy) | 28,844 | $0.00 | - | |
| Maria-Luisa Maccecchini - Director | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Maria-Luisa Maccecchini - Director | Grant or award | Stock Option (Right to Buy) | 21,152 | $0.00 | - | |
| Vijay Chandru - Director | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Vijay Chandru - Director | Grant or award | Stock Option (Right to Buy) | 17,307 | $0.00 | - | |
| Lee Troy Schalop - Director | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Lee Troy Schalop - Director | Grant or award | Stock Option (Right to Buy) | 18,460 | $0.00 | - | |
| David S. Silberstein - Director | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| David S. Silberstein - Director | Grant or award | Stock Option (Right to Buy) | 17,307 | $0.00 | - | |
| David R. Margrave - Officer | Grant or award | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Kishor G. Bhatia - Officer | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Vijay Chandru - Director | Derivative | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| Vijay Chandru - Director | Grant or award | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| Vijay Chandru - Director | Derivative | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| Vijay Chandru - Director | Grant or award | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| Kishor G. Bhatia - Officer | Derivative | Stock Option (Right to Buy) | 52,200 | $0.00 | - | |
| Kishor G. Bhatia - Officer | Grant or award | Stock Option (Right to Buy) | 52,200 | $0.00 | - | |
| Kishor G. Bhatia - Officer | Derivative | Stock Option (Right to Buy) | 17,400 | $0.00 | - | |
| Kishor G. Bhatia - Officer | Grant or award | Stock Option (Right to Buy) | 17,400 | $0.00 | - | |
| David R. Margrave - Officer | Derivative | Stock Option (Right to Buy) | 78,300 | $0.00 | - | |
| David R. Margrave - Officer | Grant or award | Stock Option (Right to Buy) | 78,300 | $0.00 | - | |
| David R. Margrave - Officer | Derivative | Stock Option (Right to Buy) | 26,100 | $0.00 | - | |
| David R. Margrave - Officer | Grant or award | Stock Option (Right to Buy) | 26,100 | $0.00 | - | |
| David S. Silberstein - Director | Derivative | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| David S. Silberstein - Director | Grant or award | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| David S. Silberstein - Director | Derivative | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| David S. Silberstein - Director | Grant or award | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| D. Jeffrey Keyser - Director | Derivative | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| D. Jeffrey Keyser - Director | Grant or award | Stock Option (Right to Buy) | 9,135 | $0.00 | - | |
| D. Jeffrey Keyser - Director | Derivative | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| D. Jeffrey Keyser - Director | Grant or award | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
 Panna Sharma - Officer | Derivative | Stock Option (Right to Buy) | 76,628 | $0.00 | - | |
| Panna Sharma - Officer | Grant or award | Stock Option (Right to Buy) | 76,628 | $0.00 | - | |
| Lee Troy Schalop - Director | Grant or award | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
LTRN insider trading FAQ
What is the latest insider trade for LTRN?
Lantern Pharma Inc. (LTRN) has filed no insider reports in the last 90 days. The most recent on record is dated 14 May 2026. The full record for LTRN runs to 16 Form 4 filings, the earliest from 19 August 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LTRN stock?
No insider purchases of LTRN were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling LTRN stock?
No insider sales of LTRN were filed in the last 90 days.
Where can I see LTRN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LTRN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lee Troy Schalop view on EDGAR
- - D. Jeffrey Keyser view on EDGAR
- - D. Jeffrey Keyser view on EDGAR
- - Maria-Luisa Maccecchini view on EDGAR
- - Vijay Chandru view on EDGAR
- - Lee Troy Schalop view on EDGAR
- - David S. Silberstein view on EDGAR
- - David R. Margrave view on EDGAR
- - Kishor G. Bhatia view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LTRN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LTRN with a 7-day demo
- LTRN on your watchlist
- Every LTRN Form 4 filing on record
- Up to 3 months of LTRN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
